CureVac gains COO and hands Florian von der Mülbe new assignment in the midst of Covid-19 vaccine troubles; As Ken Frazier retires, Merck hires chief strategy officer
→ Aiming to bounce back and trying to accentuate the positive after its mRNA Covid-19 vaccine took a major pratfall, CureVac is shaking things …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
